Danaher and NVIDIA move to build AI models into lab instruments for drug discovery

Danaher, the life sciences and diagnostics group, said on 14 October 2026 that it is working with NVIDIA to build AI into its laboratory instruments, automation and workflow software, with the stated aim of shortening the path from a model's prediction to the experimental evidence needed to act on it ¹.

What the companies have agreed

The collaboration pairs Danaher's instruments, automation technologies, lab workflow software and scientific know-how with NVIDIA's accelerated computing and AI software ¹. The technical scope named so far is specific. It covers edge computing on NVIDIA DGX Spark, data processing and analytics with RAPIDS, real-time inference, and foundation models including BioNeMo Open Models ¹. The two companies are also looking at whether NVIDIA's Cosmos world models and Omniverse digital twins can make instruments and lab workflows more responsive ¹.

The first phase is narrow. Danaher said the initial work centres on "a select group of priority instruments", with the option of extending it across more of its portfolio later ¹. Neither company has published financial terms, a list of the instruments involved or a timetable for products reaching customers ¹².

The design idea is a closed loop in which experimental results retrain models and the models propose the next experiments ¹². Kimberly Powell, NVIDIA's vice president of healthcare, said the aim was "helping researchers compress years of discovery into months" ¹. Julie Sawyer Montgomery, Danaher's chief executive, framed it as a "shared vision for more connected, adaptive and accessible innovation" ¹.

The deal builds on a project Danaher announced earlier in October: its first AI-powered autonomous lab, intended to help scientists develop custom antibodies and other molecular tools faster ². That lab combines AI, robotics and technology from several Danaher operating companies in one workflow, and sits within an internal programme to build a fleet of smart instruments that can be controlled programmatically and include agentic systems ². NVIDIA says the lab uses its BioNeMo open models in its AI protein design workflows and is designed to deliver up to 8x faster discovery of affinity reagents ³.

What it means for the market

For pharma and biotech R&D teams, the practical change is where the AI sits. Most AI in discovery today runs on models kept apart from the bench, with results moved between systems by hand. Danaher is proposing to put inference and data processing inside the instruments that generate the data ¹. If that works, the buyer of a lab instrument would also be buying into a model and data pipeline, which raises questions about lock-in. Danaher has tried to answer this in advance, saying it intends to preserve "customer choice in models, standards and technology providers" ¹.

For suppliers, the move puts a large instrument maker alongside the AI drug discovery platforms that have signed deals with big pharma this year. Danaher's route is different. It sells the tools that wet labs already run rather than a discovery service. NVIDIA, for its part, is placing its biology models with an instrument maker as well as with start-ups: on the same day it announced planned investments in London's Boltz, which builds biomolecular models for drug design, and Prima Mente, which builds biological foundation models aimed at Alzheimer's, Parkinson's and ALS ³.

Limits

The claims so far are the companies' own. The speed figure for the autonomous lab is NVIDIA's description of a design target, not a published result ³. Danaher's release is largely forward-looking and lists uncertainties around the development and use of AI in its products among its risk factors ¹. No customers, pharma partners or performance data have been named ¹².

The next public marker is NVIDIA chief executive Jensen Huang's GTC Berlin keynote on 21 October ³.